restor3d Announces Successful Limited Market Release of the Aeros™ Modular Stem Total Ankle System with Five Cases Performed on Day One
BUSINESS WIRE)--restor3d, a leader in 3D printed, personalized orthopedic implant care, proudly announces the successful limited market release of the Aeros™ Modular Stem Total Ankle System, with five cases performed on launch day, May 5, 2025, at OrthoCarolina by renowned foot and ankle specialists Dr. Kent Ellington and Aeros design team member, Dr. Samuel Ford.
'The Kinos Modular Stem system combines modularity, versatility, and simplicity in a way the TAR market has long needed,' added Dr. Ford. 'This is a platform I'm confident will appeal to both experienced and new users alike.'
The Aeros Modular Stem, the latest addition to the Kinos Total Ankle family, represents the first and only anteriorly inserted modular stem tibial implant available for Total Ankle Replacement (TAR). Cleared by the FDA for both primary and revision indications, the system enters a limited market release throughout 2025, with full commercial launch anticipated in 2026.
'We are exhilarated to see this system come to life in the OR with such a strong start,' said Dr. Samuel Ford. 'The streamlined instrumentation and thoughtful design of the Aeros Modular Stem made for an efficient intraoperative experience, and it opens new doors for both primary and complex revision ankle arthroplasty cases.'
Designed for efficiency, versatility, and ease of use, the Aeros Modular Stem requires just three trays of procedure-specific instruments, compared to up to seven trays for competitive systems. The implant is inserted through a standard anterior TAR incision, avoiding violation of the heel, calcaneus, or subtalar joint—a key differentiator from other intramedullary systems. The refined instrumentation provides a hands-free working area for streamlined tibial canal preparation, with coupled and standalone Patient Specific Resection (PSR ™) Cut Guides providing greater intraoperative flexibility, particularly in complex deformity cases. Restor3D's proprietary TIDAL Technology on all tibial and talar implants provides scientifically proven, research backed osseointegration potential, further emphasizing the role of the Kinos Total Ankle System in advancing total ankle arthroplasty.
The system is fully compatible with all existing Kinos Flat Cut Talus and bearing components, including its interchangeable Anatomic and Range articulations. In simulator testing, both articulating bearings demonstrated substantially improved polyethylene wear performance, with 200% less wear than Competitor A and 400% less than Competitor B¹. Competitors A and B were selected for comparison due to their length of time in the market and considerable clinical follow-up data presented in the literature. This advancement reflects the biomechanically accurate design of Kinos and directly addresses the growing demand for longer-lasting implants as survivorship rates improve.
Early retrospective studies are underway to validate an anticipated 30% reduction in operative time versus traditional stemmed systems—a meaningful objective given published data by Gross et al.², which links every 15-minute increase in TAR operative time with a 10% increase in complications, 33% increase in wound dehiscence, and 16% increase in reoperations.
'The Kinos Modular Stem system combines modularity, versatility, and simplicity in a way the TAR market has long needed,' added Dr. Ford. 'This is a platform I'm confident will appeal to both experienced and new users alike.'
¹ Data on File
² As presented at AOFAS 2024 Annual Meeting 'A Prospective Evaluation of a 4th Generation Total Ankle Prosthesis with Flat Cut vs Chamfer Cut Talar Component" 9/13/2024 Vancouver, British Columbia, Canada
About restor3d, Inc.
restor3d is a world leader in 3D printed patient specific musculoskeletal implants and driven by the belief that every patient deserves personalized care. The company holds proprietary expertise and intellectual property in 3D printing of osseointegrative materials, AI-based planning and design automation tools, and digital health solutions to provide seamless data-backed care to optimize individual patient outcomes. Alongside its customers, restor3d is reimagining the musculoskeletal reconstruction landscape. More information is available at www.restor3d.com.
Forward Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as 'future,' 'believes,' 'expects,' 'may,' 'will,' 'should,' 'potential,' 'estimates,' 'intends,' 'anticipates' or 'plans' or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions and current expectations but are subject to known and unknown risks and uncertainties including, without limitation, distribution challenges, market trends and demand, product efficacy and safety concerns, product or raw material availability and other supply constraints. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results. The forward-looking statements included are made only as the date of this release. The company assumes no obligation to update any information or forward-looking statement contained herein, save for any information required to be disclosed by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Sarepta suspends non-ambulatory Elevidys shipments after second death
Sarepta (SRPT) Therapeutics provided a safety update regarding Elevidys, an FDA approved gene therapy for patients with Duchenne muscular dystrophy. The company announced a second reported case of acute liver failure resulting in death. The cases of ALF to date have both occurred in non-ambulatory individuals with Duchenne. Sarepta is temporarily suspending shipments of Elevidys for non-ambulatory patients while an enhanced immunosuppressive regimen is evaluated, discussed with regulatory bodies, and put in place. For ambulatory patients, no treatment changes are being proposed and the current practice of administering corticosteroids before and after Elevidys infusion, along with post-treatment monitoring, remains the same. Sarepta has also voluntarily paused dosing in the ENVISION clinical study. FDA concurs with this action, the company said. 'The pause will allow for the evaluation of a protocol amendment to incorporate an enhanced immunosuppressive regimen for the non-ambulatory patient cohort and incorporate any additional feedback from the FDA. Regulatory alignment is needed before screening and dosing in ENVISION may resume,' Sarepta added. The company is working to immediately convene an independent group of leading experts in Duchenne and liver health to consider an enhanced immunosuppression regimen for Elevidys.
Business Wire
4 hours ago
- Business Wire
Resecurity Expands LATAM Presence Through Strategic Partnership with INFORC in Ecuador
LOS ANGELES & QUITO, Ecuador--(BUSINESS WIRE)-- Resecurity, a U.S.-based cybersecurity and threat intelligence company, is pleased to announce a new strategic partnership with INFORC ECUADOR, a leading Ecuadorian cybersecurity company that specializes in offering cybersecurity solutions and services to organizations across the region. This partnership marks a key development in Resecurity's expansion strategy across Latin America, solidifying its presence in Ecuador and further enhancing the availability of its advanced threat intelligence and cybersecurity solutions to local organizations. Founded in 2005, INFORC ECUADOR® is widely recognized for its expertise in information security compliance, secure software development, incident response (CSIRT), and offensive security testing. As a reseller of Resecurity's cybersecurity solutions, INFORC will help local organizations strengthen their cybersecurity posture by delivering Resecurity's state-of-the-art products, including the Context™ threat intelligence platform, advanced endpoint protection, and fraud prevention solutions. Through this partnership, INFORC will: Offer Resecurity's market-leading cyber threat intelligence and fraud prevention solutions to Ecuadorian enterprises and government entities. Deliver expert services related to Resecurity's platform implementation, training, and support. Collaborate with Resecurity to offer cybersecurity compliance, incident response, and intelligence services tailored to Ecuador's regulatory environment. Provide enhanced threat detection, phishing prevention, malware tracking, and brand abuse protection solutions. "Our partnership with Resecurity is a significant milestone in our mission to deliver cutting-edge cybersecurity solutions to Ecuador," said Ing. Carlos Jumbo, CEO of INFORC. "By reselling Resecurity's solutions, we can offer our clients world-class cyber threat intelligence and risk management capabilities to help them secure their operations and meet compliance requirements." "We are thrilled to partner with INFORC to bring our advanced cybersecurity solutions to Ecuador," said Gene Yoo, CEO of Resecurity."This partnership helps us further extend our presence in Latin America and equips INFORC with the tools and expertise needed to help local organizations defend against increasingly sophisticated cyber threats." The collaboration is poised to address the growing demand for cybersecurity solutions in Ecuador, especially in light of rising cyber threats targeting both public and private sector entities. INFORC's trusted status in the region, combined with Resecurity's innovative technology, will provide Ecuadorian organizations with the advanced tools necessary to proactively manage and mitigate digital risks. With this agreement, Resecurity continues its commitment to building strong relationships with regional partners across Latin America, reinforcing its role as a key player in the cybersecurity space. About Resecurity® Resecurity® is a cybersecurity company that delivers a unified endpoint protection, fraud prevention, risk management, and cyber threat intelligence platform. Known for providing best-of-breed data-driven intelligence solutions, Resecurity's services and platforms focus on early-warning identification of data breaches and comprehensive protection against cybersecurity risks. Founded in 2016, it has been globally recognized as one of the world's most innovative cybersecurity companies with the sole mission of enabling organizations to combat cyber threats regardless of how sophisticated they are. Most recently, by Inc. Magazine, Resecurity was named one of the Top 10 fastest-growing private cybersecurity companies in Los Angeles, California. As a member of InfraGard National Members Alliance (INMA), AFCEA, NDIA, SIA, FS-ISAC, and the American Chamber of Commerce in Saudi Arabia (AmChamKSA), Singapore (AmChamSG), Korea (AmChamKorea), Mexico (AmChamMX), Thailand (AmChamThailand), and UAE (AmChamDubai). To learn more about Resecurity, visit About INFORC ECUADOR® Founded in 2005, INFORC ECUADOR® is a leading Ecuadorian cybersecurity company recognized for its expertise in providing comprehensive cybersecurity services and solutions. With a strong presence in the local market, INFORC specializes in areas such as information security compliance, secure software development, incident response, penetration testing, phishing detection, and cyber intelligence services. The company also offers cybersecurity training, awareness programs, and operates a Computer Security Incident Response Team (CSIRT). INFORC's in-depth knowledge of the Ecuadorian market and its commitment to delivering top-tier security solutions make it a trusted partner for both private and public sector organizations. Learn more at
Business Wire
5 hours ago
- Business Wire
Cosmetics Industry Icon Leonard A. Lauder, Chairman Emeritus, The Estée Lauder Companies, Passes Away
NEW YORK--(BUSINESS WIRE)--It is with deep sadness that The Estée Lauder Companies Inc. (NYSE: EL) announces that Chairman Emeritus Leonard A. Lauder passed away on June 14, at the age of 92, surrounded by family. Mr. Lauder was born in 1933 in New York City, the oldest son of Estée and Joseph H. Lauder, the founders of The Estée Lauder Companies. He was a graduate of the Bronx High School of Science, the University of Pennsylvania's Wharton School, and the Officer Candidate School of the United States Navy. Mr. Lauder studied at Columbia University's Graduate School of Business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award. He formally joined Estée Lauder in 1958, and for more than six decades, Mr. Lauder was a visionary and an innovator, helping transform the business from a handful of products sold under a single brand in U.S. stores to the multi-brand, global leader in prestige beauty that it is today. 'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William P. Lauder, son and Chair, Board of Directors, The Estée Lauder Companies. 'He was the most charitable man I have ever known, believing that art and education belonged to everyone, and championing the fight against diseases such as Alzheimer's and breast cancer. Above all, my father was a man who practiced kindness with everyone he met. His impact was enormous. He believed that employees were the heart and soul of our company, and they adored him and moments spent with him. His warmth and thoughtfulness made an imprint on our company, the industry, and, of course, our family. Together with my family, The Estée Lauder Companies, and the countless people he touched, we celebrate his extraordinary life.' Mr. Lauder served as President of The Estée Lauder Companies from 1972 to 1995 and as Chief Executive Officer from 1982 through 1999. He was named Chairman in 1995 and served in that role through June 2009. Throughout his tenure at the company, Mr. Lauder consistently challenged the status quo, developing and implementing innovative sales and marketing programs that revolutionized the beauty industry. He created the company's first research and development laboratory, brought in professional management at every level, and was the driving force behind The Estée Lauder Companies' international expansion, helping to increase the company's sales and profits exponentially. A legendary brand builder, Mr. Lauder led the launch of many brands including Aramis, Clinique, and Lab Series, among others. Until his death, he remained deeply involved in the company's acquisition strategy, including the acquisitions of Aveda, Bobbi Brown, Jo Malone London, La Mer, and M∙A∙C. Speaking for The Estée Lauder Companies, President and Chief Executive Officer Stéphane de La Faverie said, 'Leonard Lauder was beloved by many and will be missed tremendously. To our employees at The Estée Lauder Companies, he was an inspiration and a champion. To the industry, he was an icon and pioneer, earning respect worldwide. His energy and vision helped shape our company and will continue to do so for generations to come. He was a deeply compassionate leader who cared profoundly about every person in the company. I feel privileged to have worked with Leonard, who has been the best mentor I could have dreamt to learn from. He will be remembered by all of us.' During his many years as Chairman Emeritus, Mr. Lauder was closely involved in the business and day-to-day operations of the company and was a constant fixture at The Estée Lauder Companies' global headquarters in New York and at our stores and counters across the globe until the time of his death. Mr. Lauder believed that each of his colleagues was like a member of his family and treated them as such. The values that continue to set the company apart are the values he so strongly believed in and embodied, most notably generosity of spirit and kindness toward all. Perhaps the role Mr. Lauder was most proud of was the unofficial one as The Estée Lauder Companies' 'chief teaching officer.' He believed that a company's wealth is its people and focused on mentoring and fostering growth within the company's diverse talent pool. He believed strongly in the importance of recognition and gratitude and was a tireless advocate for employees. At the onset of the global pandemic in 2020, Mr. Lauder was instrumental in setting up the ELC Cares Employee Relief Fund to support the physical, mental, and emotional well-being of employees and their families. Mr. Lauder was deeply involved in medical research, education, art, foreign policy, and philanthropy, and the marks he made on those worlds were transformational. Mr. Lauder believed passionately in the importance of public access to art and museums, which inspired his philosophy that the primary role of a collector was to conserve, not possess. He was a long-time supporter of the Metropolitan Museum of Art (the Met) and, in 2013, pledged his 78-piece collection of Cubist art to the museum in the largest single philanthropic gift in the Met's history. He later added five major works to that promised gift. In concert with his Cubist collection donation, he helped establish the Leonard A. Lauder Research Center for Modern Art at the Met to support a robust program of fellowships, focused exhibitions, and public lectures. Along with his prominent presence at the Met, he also served as the Whitney Museum of American Art's Chairman Emeritus and a trustee from 1977 to 2011. Throughout his life, he donated works of art and endowed curatorial positions and research departments to numerous institutions. Mr. Lauder was a long-time advocate of cancer research and served as Honorary Chairman of the board of directors at the Breast Cancer Research Foundation, the organization his beloved late-wife, Evelyn H. Lauder, founded in 1993. He also championed the fight against Alzheimer's by co-founding and leading the Alzheimer's Drug Discovery Foundation with his brother, Ronald S. Lauder, which supports cutting-edge drug research. Mr. Lauder remained actively engaged with these organizations until his death, and they were extraordinarily dear to his heart. Remembering his brother, Ronald S. Lauder, Chairman, Clinique Laboratories, LLC at The Estée Lauder Companies, said, 'Leonard was a wonderful brother and a devoted husband, father, grandfather, great-grandfather, uncle, colleague, and friend. But his legacy extends far beyond being the heart of our family. His impact will be felt for generations to come thanks to his tireless philanthropy, advocacy, and creativity in tackling some of the world's greatest challenges. The number of lives he touched and positively impacted across all his endeavors is immeasurable. His passion and generosity have inspired us all, and there are no words to express how much he will be missed.' 'My father was a remarkable man, a leader in business, a devoted philanthropist, and a deeply loving father, grandfather, and great-grandfather,' said Gary M. Lauder, son and Member, Board of Directors, The Estée Lauder Companies. 'His energy, sharp intellect, and generous spirit touched the lives of so many across the world. To me, he was also a constant source of encouragement, wisdom, and love. His legacy is vast, not only in the beauty industry, but in the countless lives improved by his charitable efforts and his passionate commitment to the arts, education, and healthcare. He was not only well-respected and admired, but he was also adored by his employees and colleagues. This affection stands out for me. While we mourn his passing, we also celebrate his extraordinary life, his lasting contributions, and the values he instilled in all of us: integrity, curiosity, and the importance of giving back. He will be missed more than words can express.' Mr. Lauder believed in the value of education and supported a variety of academic institutions. He was an emeritus trustee of the University of Pennsylvania and a founding member of the board of governors of its Joseph H. Lauder Institute of Management and International Studies, along with his brother, Ronald. His passion for education continued into the public space, having supported several schools in the New York area and receiving the honor of being an inductee into the Bronx High School of Science Hall of Fame in 2017. When the pandemic in 2020 magnified the nation's acute shortage of quality primary care in underserved communities, Mr. Lauder worked with the University of Pennsylvania to create a tuition-free program to educate nurse practitioners. His donation of $125 million, the largest gift ever to an American nursing school, made possible the Leonard A. Lauder Community Care Nurse Practitioner Program at the University of Pennsylvania. Mr. Lauder worked throughout his life to promote dialogue among governments, political and non-governmental organizations, and the public and private sectors, believing that this interdisciplinary dialogue is crucial to progress. He served as a member of the Council on Foreign Relations and as Chairman Emeritus and a lifetime trustee on the board of directors at the Aspen Institute. He felt that public service was a person's duty and, in addition to his time in the U.S. Navy, later served on the Advisory Committee for Trade Negotiations under President Ronald Reagan from 1983–1987. Throughout his lifetime, Mr. Lauder was honored with a myriad of awards, including the 'Lone Sailor' Award given by the U.S. Navy Supply Corps Foundation, the Légion d'Honneur given by the government of France, the Women's Leadership Award given by the Lincoln Center Corporate Fund Women's Leadership Council, and the Palazzo Strozzi Renaissance Man of the Year Award. In 2020, he was inducted into the Retail Hall of Fame by the World Retail Congress. The Lauder family received the esteemed 2011 Carnegie Medal of Philanthropy in recognition of its long-standing commitment to philanthropy and public service. In 2014, Mr. Lauder was named a Living Landmark by the New York Landmarks Conservancy. Mr. Lauder and Ms. Glickman Lauder also received the Gordon Parks Foundation Patron of the Arts Award in 2016. Mr. Lauder shared many of the lessons he learned in business and life in his memoir, The Company I Keep: My Life in Beauty, published to great acclaim in 2020. He was married to Evelyn H. Lauder, Senior Corporate Vice President at The Estée Lauder Companies and the Founder of the Breast Cancer Research Foundation, from 1959 until she passed away in 2011. On January 1, 2015, Mr. Lauder married Judy Glickman Lauder, a philanthropist and internationally recognized photographer whose work is represented in more than 300 public and private collections, including the J. Paul Getty Museum, the Whitney Museum of Art, the Metropolitan Museum of Art, and the United States Holocaust Museum. Mr. Lauder considered himself lucky in love and believed that lightning really could strike twice. From the beginning, he was devoted to family. He loved his parents and adored his brother, Ronald, and the family Ronald built with Jo Carole. His nieces and their families held a special place in his heart. Mr. Lauder was grateful to his wife, Judy, for widening his family circle and cherished his stepchildren and their families. But mostly, he was extraordinarily proud of both of his sons, their families, and his grandchildren and great-grandchildren. He loved them so dearly. Mr. Lauder was a true visionary, fearless leader, and cherished friend to so many. He was the beacon of our company and the north star of an entire industry. The world is a better place because Leonard Lauder was in it. The Estée Lauder Companies extends our deepest sympathies to the entire Lauder family during this exceedingly difficult time. Mr. Lauder is survived by his wife, Judy Glickman Lauder; his son William P. Lauder; his son Gary M. Lauder and wife, Laura Lauder; five grandchildren, Rachel, Danielle, Djuna-Bear, Joshua, Eliana, two great-grandchildren, many stepchildren and step grandchildren, as well as his brother, Ronald S. Lauder, and wife, Jo Carole Lauder, and their daughters, Aerin Lauder and Jane Lauder. A private service will be held for friends and family. For those who wish, in lieu of flowers, memorial donations may be made to the Breast Cancer Research Foundation and the Alzheimer's Drug Discovery Foundation. The Estée Lauder Companies Inc. (ELC) is one of the world's leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company's products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
